Last Updated : August 10, 2023
Details
Generic Name:
bevacizumab and lomustine
Project Status:
Active
Therapeutic Area:
Recurrent glioblastoma multiform
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0318-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with glioblastoma.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 06, 2023 |
|---|---|
| Call for patient/clinician input closed | May 02, 2023 |
| Clarification: - No patient input submission received | |
| Call for industry input open | March 06, 2023 |
| Call for industry input closed | May 02, 2023 |
| Review initiated | March 06, 2023 |
| Expert committee meeting (initial) | October 17, 2023 |
| Draft recommendation posted for stakeholder feedback | November 02, 2023 |
| End of feedback period | November 17, 2023 |
Last Updated : August 10, 2023